Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 401Triple Negative Breast Neoplasms 64Neoplasm Metastasis 50Neoplasms 19Breast Neoplasms, Male 14Colorectal Neoplasms 13Brain Neoplasms 13Stomach Neoplasms 11Pancreatic Neoplasms 11Colonic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Inflammatory Breast Neoplasms 6HER2-positive Breast Cancer 6Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Advanced Breast Cancer 5Rectal Neoplasms 4HER2 Positive Metastatic Breast Cancer 4Breast Cancer Metastatic 4Sarcoma 3Prostatic Neoplasms 3Meningeal Neoplasms 3Lymphoma, Non-Hodgkin 3Gallbladder Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Unknown Primary 2

Interventions

Trastuzumab 3pyrotinib 2pertuzumab 2Fulvestrant 2tucatinib 1palbociclib 1disitamab vedotin 1atezolizumab 1RC48 antibody 1Drug Therapy 1Docetaxel 1Capecitabine 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × Capecitabine × Breast × Clear all
NCT05042791 2024-02-09

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

Jiangxi Provincial Cancer Hospital

Phase 2 Unknown
362 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡